Table 3.
Details of dashboards accessed by the respondents.
| Dashboards Accessed | Responses (n = 114) |
|---|---|
| Integrated medicines availability dashboard | 95 (83.3%) |
| COVID-19 vaccine dashboard | 62 (54.4%) |
| Integrated medicines availability dashboard—trend analysis | 62 (54.4%) |
| Historic dashboards—hospital level data only | 32 (28.1%) |
| Historic dashboards—primary healthcare level data only | 32 (28.1%) |
| COVID-19 PPE dashboard | 31 (27.2%) |
| TEE/TLD transition dashboard | 27 (23.7%) |
| Supplier management dashboard | 27 (23.7%) |
| COVID-19 supply chain | 25 (21.9%) |
| Rx API—facilities connectivity report | 20 (17.5%) |
| Demand planning dashboard | 17 (14.9%) |
| Minimum/maximum dashboard | 2 (1.8%) |
| Usage of NSC by users | 1 (0.9%) |
Nota Bene: There were 114 completed responses regarding the details of dashboards accessed via suitable technologies; PPE: Personal Protective Equipment; TEE/TLD: Tenofovir, Emtricitabine, Efavirenz/Tenofovir, Lamivudine, Dolutegravir; Rx API: RxSolution Application Programming Interface; NSC: National Surveillance Centre.